JP4681808B2 - 結晶形 - Google Patents

結晶形 Download PDF

Info

Publication number
JP4681808B2
JP4681808B2 JP2003518521A JP2003518521A JP4681808B2 JP 4681808 B2 JP4681808 B2 JP 4681808B2 JP 2003518521 A JP2003518521 A JP 2003518521A JP 2003518521 A JP2003518521 A JP 2003518521A JP 4681808 B2 JP4681808 B2 JP 4681808B2
Authority
JP
Japan
Prior art keywords
fluvastatin sodium
powder
diffraction pattern
ray diffraction
relative humidity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003518521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501838A (ja
JP2005501838A5 (https=
Inventor
ファン・デル・スハーフ，パウル・アドリアーン
マルコッリ，クラウディア
シェラギエヴィッツ，マルティン
ブルクハルト，アンドレアス
ヴォレブ，ハインツ
ヴォレブ，アンネマリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Holding AG filed Critical Ciba Holding AG
Publication of JP2005501838A publication Critical patent/JP2005501838A/ja
Publication of JP2005501838A5 publication Critical patent/JP2005501838A5/ja
Application granted granted Critical
Publication of JP4681808B2 publication Critical patent/JP4681808B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
JP2003518521A 2001-08-03 2002-07-25 結晶形 Expired - Fee Related JP4681808B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01810756 2001-08-03
PCT/EP2002/008276 WO2003013512A2 (en) 2001-08-03 2002-07-25 Crystalline forms of fluvastatin sodium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010165635A Division JP2010265308A (ja) 2001-08-03 2010-07-23 結晶形

Publications (3)

Publication Number Publication Date
JP2005501838A JP2005501838A (ja) 2005-01-20
JP2005501838A5 JP2005501838A5 (https=) 2006-01-05
JP4681808B2 true JP4681808B2 (ja) 2011-05-11

Family

ID=8184071

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003518521A Expired - Fee Related JP4681808B2 (ja) 2001-08-03 2002-07-25 結晶形
JP2010165635A Pending JP2010265308A (ja) 2001-08-03 2010-07-23 結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010165635A Pending JP2010265308A (ja) 2001-08-03 2010-07-23 結晶形

Country Status (16)

Country Link
US (1) US6696479B2 (https=)
EP (1) EP1429757B8 (https=)
JP (2) JP4681808B2 (https=)
KR (1) KR100975782B1 (https=)
CN (2) CN102516150A (https=)
AR (1) AR036205A1 (https=)
AT (1) ATE391502T1 (https=)
AU (1) AU2002333271B2 (https=)
CA (1) CA2454072A1 (https=)
DE (1) DE60226044T2 (https=)
ES (1) ES2304140T3 (https=)
HU (1) HUP0401141A3 (https=)
IL (2) IL159861A0 (https=)
PL (1) PL366905A1 (https=)
RU (1) RU2334738C2 (https=)
WO (1) WO2003013512A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US20050107359A1 (en) * 2002-07-26 2005-05-19 Van Der Schaaf Paul A. Crystalline polymorphic and amorphous forms of benazepril hydrochloride
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
KR20070092994A (ko) * 2003-06-18 2007-09-14 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 결정형 ｘｉｖ, ｌｘｘｉｉｉ,ｌｘｘｉｘ, ｌｘｘｘ 및 ｌｘｘｘｖｉｉ, 이의 제조 방법,이를 포함하는 조성물 및 이를 사용하는 방법
US7368581B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
EP1667791A1 (en) * 2003-10-06 2006-06-14 Solvias AG Process for the parallel detection of crystalline forms of molecular solids
US7432380B2 (en) 2003-10-16 2008-10-07 Ciba Specialty Chemicals Corp. Crystalline form of Fluvastatin sodium
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005080332A1 (en) * 2004-01-14 2005-09-01 Cadila Healthcare Limited Novel form of fluvastatin sodium
EP1711493A2 (en) * 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
WO2006085338A2 (en) * 2005-02-11 2006-08-17 Jubilant Organosys Limited Novel polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
WO2007039784A2 (en) * 2005-10-06 2007-04-12 Wockhardt Limited A novel crystalline polymorph of fluvastatin sodium and process for preparing it
EP1948637A4 (en) * 2005-11-14 2010-09-08 Hetero Drugs Ltd PROCESS FOR AMORPHES ESOMEPRAZOLE
DE07752084T1 (de) * 2006-02-27 2008-06-05 Teva Pharmaceutical Industries Ltd. Neuartige formen von fluvastatin-natrium und herstellung davon
WO2009122425A1 (en) * 2008-04-04 2009-10-08 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
JP6115288B2 (ja) * 2012-04-27 2017-04-19 株式会社島津製作所 質量分析におけるピーク検出方法及びそのシステム
TW201806928A (zh) * 2016-07-01 2018-03-01 第一三共股份有限公司 胺基羧酸之酸加成鹽的結晶及其製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
JPS60500015A (ja) * 1982-11-22 1985-01-10 サンド・アクチエンゲゼルシヤフト メバロラクトン同族体とその誘導体、これらの製造法およびこれらを含有する製薬学的組成物
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DK0907639T3 (da) * 1996-06-24 2003-06-23 Novartis Ag Polymorfe forbindelser
JP2004513112A (ja) * 2000-10-31 2004-04-30 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド フルバスタチンナトリウムの結晶形

Also Published As

Publication number Publication date
CA2454072A1 (en) 2003-02-20
HUP0401141A3 (en) 2011-07-28
US6696479B2 (en) 2004-02-24
ATE391502T1 (de) 2008-04-15
CN1536999A (zh) 2004-10-13
JP2005501838A (ja) 2005-01-20
CN1536999B (zh) 2012-08-08
CN102516150A (zh) 2012-06-27
DE60226044T2 (de) 2009-05-14
IL159861A0 (en) 2004-06-20
US20030032666A1 (en) 2003-02-13
ES2304140T3 (es) 2008-09-16
JP2010265308A (ja) 2010-11-25
RU2004106528A (ru) 2005-07-27
DE60226044D1 (de) 2008-05-21
KR20040022226A (ko) 2004-03-11
WO2003013512A2 (en) 2003-02-20
EP1429757A2 (en) 2004-06-23
HUP0401141A2 (hu) 2004-09-28
WO2003013512A3 (en) 2003-11-20
KR100975782B1 (ko) 2010-08-17
RU2334738C2 (ru) 2008-09-27
IL159861A (en) 2009-02-11
AU2002333271B2 (en) 2007-08-09
EP1429757B1 (en) 2008-04-09
AR036205A1 (es) 2004-08-18
PL366905A1 (en) 2005-02-07
EP1429757B8 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
JP4681808B2 (ja) 結晶形
AU2002333271A1 (en) Crystalline forms of fluvastatin sodium
US6858643B2 (en) Crystalline forms of Fluvastatin sodium
CN1273449C (zh) 阿伐他汀的晶型
IE59901B1 (en) Piperidine derivative, its preparation, and its use as medicament
AU2002223639A1 (en) Crystalline forms of fluvastatin sodium
CN1501910A (zh) 盐酸文拉法辛的晶形
US20040063961A1 (en) Crystalline forms of cerivastatin sodium
US6800782B2 (en) Anhydrous crystalline forms of gabapentin
CN1073439A (zh) 非晶形(喹啉-2-基甲氧基)吲哚
US20060241167A1 (en) Crystalline form of fluvastatin sodium
WO2006030304A2 (en) Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
CN1109677C (zh) 氨基苯磺酸衍生物的单水合物及其制备方法
WO2007039784A2 (en) A novel crystalline polymorph of fluvastatin sodium and process for preparing it
AU2002330220A1 (en) New anhydrous crystalline forms of gabapentin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100723

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110207

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140210

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees